Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T09:58:33.072Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment failure in emergency department patients with cellulitis

Published online by Cambridge University Press:  21 May 2015

Heather Murray ,
Ian Stiell  and
George Wells
Heather Murray*
Affiliation:
Department of Emergency Medicine, Queen's University, Kingston, Ont.
Ian Stiell
Affiliation:
Department of Emergency Medicine, University of Ottawa, Ottawa, Ont.
George Wells
Affiliation:
Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ont.
*
Department of Emergency Medicine, Kingston General Hospital, 76 Stuart St, Kingston ON K7L 2V7; 613 548-2368, 613 548-1374, [email protected]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To identify the rate of treatment failure in emergency department patients with cellulitis.

Methods:

This prospective observational convenience study enrolled adult patients with uncomplicated cellulitis. Physicians performed a standardized assessment prior to treatment. To calculate the interrater reliability of the assessment, duplicate data collection forms were completed on a small subsample of patients. Treatment failure was defined as the occurrence of any one of the following events after the initial emergency department visit: incision and drainage of abscess; change in antibiotics (not due to allergy/intolerance); specialist consultation; or, hospital admission. Comparison of means and proportions between the 2 groups was performed with univariate associations, using parametric or non-parametric tests where appropriate.

Results:

Seventy-five patients were enrolled; 57% were male, the mean age was 48 (standard deviation 19), 71 (95%) patients had extremity cellulitis and 10 (13%) had abscess with cellulitis. Fourteen episodes (18.7%, 95% confidence interval [CI] 11%–28%) were classified as treatment failures, with an oral antibiotic failure rate of 6.8% (95% CI 2%–22%) and an emergency department-based intravenous antibiotic failure rate of 26.1% (95% CI 16%–40%). Patients with treatment failure were older (mean age 59 yr v. 46 yr, p = 0.02) and more likely to have been taking oral antibiotics at enrolment (50% v. 16.4%, p = 0.01). Patients with a larger surface area of infection were also more likely to fail treatment (465.1 cm2 v. 101.5 cm2, p < 0.01). Interrater agreement was high for the presence of fever (kappa 1.0) and the size of surface area of infection (intraclass correlation coefficient 0.98), but low for assessments of both severity (kappa 0.35) and need for admission (kappa 0.46).

Conclusions:

The treatment of cellulitis with daily emergency department–based intravenous antibiotics has a failure rate of more than 25% in our centre. Cellulitis patients with a larger surface area of infection and previous (failed) oral therapy are more likely to fail treatment. Further research should focus on defining eligibility for treatment with emergency department-based intravenous antibiotics.

Keywords

cellulitisskin and soft tissue infectionstreatment failure
Type
EM Advances • Innovations en MU
Information
Canadian Journal of Emergency Medicine , Volume 7 , Issue 4 , July 2005 , pp. 228 - 234
Copyright
Copyright © Canadian Association of Emergency Physicians 2005

References

1.Brown, G, Chamberlain, R, Goulding, J, Clarke, A. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med 1996;14(5):547–51.CrossRefGoogle ScholarPubMed
2.Dong, SL, Kelly, KD, Oland, RC, Holroyd, BR, Rowe, BH. ED management of cellulitis: a review of five urban centers. Am J Emerg Med 2001;19(7):535–40.Google Scholar
3.Grayson, ML, McDonald, M, Gibson, K, Athan, E, Munckhof, WJ, Paull, , et al.Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infec Dis 2002;34(11):1440–8.CrossRefGoogle ScholarPubMed
4.Deery, HG. Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Infect Dis Clini N Am 1998;12(4):935–49, vii.CrossRefGoogle ScholarPubMed
5.Leder, K, Turnidge, JD, Grayson, ML. Home-based treatment of cellulitis with twice-daily cefazolin. Med Australia 1998; 169(10):519–22.CrossRefGoogle ScholarPubMed
6.Morris, A. Cellulitis and erysipelas. Clin Evid 2002;(7):1483–7.Google Scholar
7.Dilemmas when managing cellulitis. Drug Ther Bull 2003; 41(6):43–6.Google Scholar
8.Cox, VC, Zed, PJ. Once-daily cefazolin and probenecid for skin and soft tissue infections. Ann Pharmacother 2004;38(3):458–63.CrossRefGoogle ScholarPubMed
9.Murray, H. Cellulitis in the emergency department: developing and testing objective outcome measures [masters thesis]. University of Ottawa, 2002.Google Scholar
10.Eron, LJ, Lipsky, BA, Low, DE, Nathwani, D, Tice, AD, Volturo, GA, et al.Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003;52(suppl 1):i3–17.CrossRefGoogle Scholar
11.Calandra, GB, Norden, C, Nelson, JD, Mader, JT. Evaluation of new anti-infective drugs for the treatment of selected infections of the skin and skin structure. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15(suppl 1):S148-54.Google Scholar
12.Bibliography. Current world literature. Skin and soft tissue infections. Curr Opin Infect Dis 2004;17(2):149–57.Google Scholar
13.Montalto, M, Dunt, D. Home and hospital intravenous therapy for two acute infections: an early study. Aust N Z J Med 1997; 27(1):19–23.Google Scholar
14.Hoogewerf, SEC, Stiell, IG, Vandemheen, K. Single dose intravenous cefazolin and oral cephalexin compared to intravenous cefazolin for the treatment of cellulitis [abstract]. Can J Emerg Med 1999;1(3):184.Google Scholar
15.Zed, PJ, Harder, C, Harrison, DW, Pursell, RA. Efficacy of once daily cefazolin/probenecid for the outpatient management of skin and soft tissue infections [abstract]. Can J Emerg Med 2001; 3(2):139–40.Google Scholar